NCT04161248 2026-02-02
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase EARLY_PHASE1 Recruiting
Clinical Trials
7 trialsNCT06662227 2026-01-20
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT07205315 2025-12-26
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
Phase EARLY_PHASE1 Recruiting
NCT06446128 2025-08-21
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1 Recruiting
NCT06976437 2025-07-10
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Affiliated Hospital of Jiangsu University
Phase EARLY_PHASE1 Recruiting
NCT06716164 2024-12-04
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT06693973 2024-11-19
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting